Skip to main content
Swing Capital

Sun Pharmaceutical Industries Ltd

NSE: SUNPHARMA BSE: 524715Pharma

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

₹1,905
52W: ₹1547 — ₹1910
PE 105 · Book ₹99.2 · +1820% vs book
Market Cap₹4,57,121 Cr
Stock P/E105Price to Earnings
ROCE16.8%Return on Capital
ROE17.8%Return on Equity
Div. Yield0.85%Face Value ₹1

Strengths

  • +Company has been maintaining a healthy dividend payout of 122%

Weaknesses

  • −Stock is trading at 19.1 times its book value
  • −Company has high debtors of 186 days.

Shareholding Pattern

Promoters54.48%
FIIs15.94%
DIIs21%
Public8.48%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%
FIIs17.23%18.01%▲0.818.04%▲0.017.96%▼0.117.26%▼0.716.55%▼0.716.12%▼0.415.94%▼0.2
DIIs19.17%18.48%▼0.718.43%▼0.118.58%▲0.119.38%▲0.820.12%▲0.720.72%▲0.621%▲0.3
Public9%8.89%▼0.18.92%▲0.08.86%▼0.18.76%▼0.18.72%▼0.08.57%▼0.28.48%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales5,0965,0745,6394,4985,1226,1817,1865,5954,5485,688
Expenses3,7103,7153,7463,7373,7914,4764,1963,6853,3653,929
Operating Profit1,3861,3591,8947611,3321,7052,9891,9101,1841,759
OPM %27%27%34%17%26%28%42%34%26%31%
Net Profit8897218682388381,1562,000745564705
EPS ₹3.73.013.620.993.494.828.343.112.352.94

AI Insights

Revenue Trend

TTM revenue at ₹23,016Cr, up 0.1% YoY. OPM at 34%.

Debt Position

Borrowings at ₹13,339Cr. Debt-to-equity ratio: 0.57x. Moderate leverage.

Capex Cycle

CWIP at ₹769Cr (10% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 21% (+1.35pp change). FIIs: 15.94% (-0.54pp change). Promoters hold 54.48%.

Margin & Efficiency

ROCE improving from 0% (Mar 2014) to 17% (Mar 2025). Working capital days: -5.

Valuation

PE 105x with 16.8% ROCE. Price is 1820% above book value of ₹99.2. Dividend yield: 0.85%.

Recent Announcements